Douglas Lind

Douglas Lind is a seasoned professional in the life sciences industry with over 20 years of experience.1 He joined BioMark Capital as Managing Director in November 2013.12

Career Background

Prior to his current role, Lind served as Managing Director at Burrill & Company and GBP Capital, a Greenwich, Connecticut-based healthcare venture firm.1 His career has spanned various aspects of the life sciences sector:

• Clinical Medicine: Lind practiced clinical medicine, serving as an attending physician at St. Elizabeth's Hospital in Boston, a major teaching affiliate of Tufts University School of Medicine.1

• Wall Street Analyst: He worked as a top-tier equity research analyst, covering biotechnology companies at Morgan Stanley from 1997 to 2002 and at PaineWebber from 1995 to 1997.1

• Venture Capitalist: Throughout his career, Lind has focused on identifying promising disruptive technologies and visionary leadership in the healthcare sector.1

Education and Expertise

Dr. Lind is a graduate of the University of Iowa College of Medicine and completed his residency training in internal medicine at Tufts University School of Medicine.1 His expertise lies in identifying high-value solutions to pressing medical needs within the biotechnology and healthcare industries.1

Current Responsibilities

As Managing Director at BioMark Capital, Lind likely plays a key role in:

• Evaluating investment opportunities in the life sciences sector
• Managing portfolio companies
• Providing strategic guidance to healthcare and biotechnology startups

Additional Roles

Douglas Lind currently serves on the board of directors of Opus Bio and HyperMed Imaging.13 He is also listed as a Co-President & Director at TMune Therapeutics, Inc.4

Douglas Lind's LinkedIn profile can be found under the username douglas-lind-698970b, confirming his current position as Managing Director at BioMark Capital since November 2013.2